title: Dose escalation may be effective in patients with psoriasis after treatment failure or suboptimal response, but switching to adalimumab is the most cost-effective measure in different scenarios.
authors.forename: L
authors.initials: L
authors.lastname: Puig
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D003879:Dermatologic Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents